Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2026)
Xeris Biopharma Holdings (XERS) posted Return on Capital Employed of 13.34% for Q1 2026, up 43.19% on a QoQ basis from 9.31% in Q4 2025, and up 2337.0% year-over-year from 0.55% in Q1 2025.
Xeris Biopharma Holdings (XERS) Return on Capital Employed (2021 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 13.34% for Q1 2026.
- Quarterly Return on Capital Employed rose 2337.0% year-over-year to 13.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.34% (up 2337.0% YoY) and the FY2025 annual result came in at 10.22%, up 2534.0% from the prior year.
- Return on Capital Employed was 13.34% for Q1 2026 at Xeris Biopharma Holdings, up from 9.31% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 13.34% in Q1 2026 and bottomed at 50.09% in Q1 2022.
- A 5-year average of 18.91% and a median of 19.13% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed surged 5023 bps — and 2024, when it jumped 127 bps.
- Xeris Biopharma Holdings' Return on Capital Employed stood at 32.76% in 2022, then soared by 42 bps to 19.13% in 2023, then climbed by 21 bps to 15.18% in 2024, then surged by 161 bps to 9.31% in 2025, then soared by 43 bps to 13.34% in 2026.
- Business Quant data shows XERS's Return on Capital Employed at 13.34% in Q1 2026, 9.31% in Q4 2025, and 4.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 13.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.34% |
| Dec 31, 2025 | 9.31% |
| Sep 30, 2025 | 4.15% |
| Jun 30, 2025 | -4.27% |
| Mar 31, 2025 | -10.03% |
| Dec 31, 2024 | -15.18% |
| Sep 30, 2024 | -19.19% |
| Jun 30, 2024 | -14.37% |
| Mar 31, 2024 | -17.53% |
| Dec 31, 2023 | -19.13% |
| Sep 30, 2023 | -20.45% |
| Jun 30, 2023 | -25.76% |
| Mar 31, 2023 | -26.30% |
| Dec 31, 2022 | -32.76% |
| Sep 30, 2022 | -47.49% |
| Jun 30, 2022 | -45.76% |
| Mar 31, 2022 | -50.09% |
| Dec 31, 2021 | -82.98% |